Alpelisib plus fulvestrant in patients with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated advanced breast cancer (ABC) previously treated with cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) + aromatase inhibitor (AI): 18-month follow-up of BYLieve Cohort A

被引：2
|
作者：
Ciruelos, Eva M.
Lerebours, Florence
Rugo, Hope S.
Ruiz-Borrego, Manuel
Drullinsky, Pamela
Prat, Aleix
Bachelot, Thomas
Neven, Patrick
Park, Yeon Hee
Turner, Nicholas
Juric, Dejan
Gu, Ennan
Arce, Christina H.
Akdere, Murat
Chia, Stephen
机构：
来源：
CANCER RESEARCH | 2022年 / 82卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS21-P1-18-03
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1-18-03
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Overall survival (OS) with palbociclib plus fulvestrant in women with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Analyses from PALOMA-3
    Cristofanilli, M.
    Slamon, D. J.
    Ro, J.
    Bondarenko, I.
    Im, S-A.
    Masuda, N.
    Colleoni, M.
    DeMichele, A.
    Loi, S.
    Verma, S.
    Iwata, H.
    Harbeck, N.
    Loibl, S.
    Andre, F.
    Theall, K. Puyana
    Huang, X.
    Giorgetti, C.
    Bartlett, C. Huang
    Turner, N. C.
    ANNALS OF ONCOLOGY, 2018, 29
  • [42] SUMIT-BC: Phase 2 randomized study of fulvestrant with or without the cyclin-dependent kinase 7 inhibitor (CDK7i) samuraciclib in advanced hormone receptor positive (HR plus ) breast cancer after CDK4/6i
    Clack, Glen
    Aksoy, Sercan
    Bellet-Ezquerra, Meritxell
    Bermejo, Begona
    Arslan, Cagatay
    Castro-Henriques, Maria
    Cicin, Irfan
    Gumus, Mahmut
    Hinojo-Gonzalez, Carmen
    Karadurmus, Nuri
    Cervantes, Denisse Lee
    Mejorada, Rebeca Lozano
    Jimenez, Emmanuel de la Mora
    Anton, Fernando Moreno
    Pernas, Sonia
    Pluard, Timothy
    del Valle, Carlos Zuloaga Fernandez
    Yazici, Ozan
    McIntosh, Stuart
    CANCER RESEARCH, 2024, 84 (09)
  • [43] Abemaciclib, a third CDK 4/6 inhibitor for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer
    El Hachem, Georges
    Gombos, Andrea
    Awada, Ahmad
    EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (01) : 81 - 92
  • [44] COST-EFFECTIVENESS OF RIBOCILIB PLUS NONSTEROIDAL AROMATASE INHIBITOR (NSAI) IN HORMONE RECEPTOR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HR+/HER2-) ADVANCED BREAST CANCER (ABC): A CANADIAN HEALTHCARE PERSPECTIVE
    Stellato, D.
    Thabane, M.
    Chandiwana, D.
    Lanoue, B.
    Delea, T. E.
    VALUE IN HEALTH, 2020, 23 : S39 - S39
  • [45] Phase I/Ib Trial of Inavolisib Plus Palbociclib and Endocrine Therapy for PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast Cancer
    Jhaveri, Komal L.
    Accordino, Melissa K.
    Bedard, Philippe L.
    Cervantes, Andres
    Gambardella, Valentina
    Hamilton, Erika
    Italiano, Antoine
    Kalinsky, Kevin
    Krop, Ian E.
    Oliveira, Mafalda
    Schmid, Peter
    Saura, Cristina
    Turner, Nicholas C.
    Varga, Andrea
    Cheeti, Sravanthi
    Hilz, Stephanie
    Hutchinson, Katherine E.
    Jin, Yanling
    Royer-Joo, Stephanie
    Peters, Ubong
    Shankar, Noopur
    Schutzman, Jennifer L.
    Juric, Dejan
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (33)
  • [46] Real-world clinical outcomes in patients receiving cyclin-dependent kinase 4/6 inhibitors (iCDK 4/6) for hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer in Mexico.
    Rodriguez, Benigno
    Lopez Zepeda, Lorena
    Noguez-Ramos, Alejandro
    Vazquez Juarez, Daniela
    Camacho Limas, Christian Patricio
    Regalado Porras, Gabriela Olivia
    Salcedo, Ivonne
    Rivera, Samuel
    Aguayo, Alvaro
    Blanco Vazquez, Yazmin Carolina
    Lopez Galindo, Angel Azael
    Shveid Gerson, Daniela
    Perez-Zincer, Fernando
    Alberto Serrano, Juan
    Fabian Martinez-Herrera, Jose
    Olivares, Guillermo
    Villalobos, Alberto
    Gonzalez De Leon, Cesar
    Gerson, Raquel
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [47] Intrinsic tumor subtype in hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (ABC) treated with cyclin-dependent kinase 4/6 inhibitors (CDK 4/6i) and endocrine therapy (ET) - a retrospective analysis of real world data
    Martins, T.
    Vitorino, M.
    Mendes, A.
    Vicente, R.
    Del Rio, A.
    Santos, C.
    EUROPEAN JOURNAL OF CANCER, 2022, 175 : S68 - S69
  • [48] Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus fulvestrant: a US Food and Drug Administration pooled analysis
    Gao, Jennifer J.
    Cheng, Joyce
    Prowell, Tatiana M.
    Bloomquist, Erik
    Tang, Shenghui
    Wedam, Suparna B.
    Royce, Melanie
    Krol, Danielle
    Osgood, Christy
    Ison, Gwynn
    Sridhara, Rajeshwari
    Pazdur, Richard
    Beaver, Julia A.
    Amiri-Kordestani, Laleh
    LANCET ONCOLOGY, 2021, 22 (11): : 1573 - 1581
  • [49] COST-EFFECTIVENESS OF RIBOCILIB PLUS FULVESTRANT (R plus F) VS FULVESTRANT (FUL) IN HORMONE RECEPTOR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HR+/HER2-) ADVANCED BREAST CANCER (ABC): A CANADIAN HEALTHCARE PERSPECTIVE
    Stellato, D.
    Thabane, M.
    Chandiwana, D.
    Lanoue, B.
    Delea, T. E.
    VALUE IN HEALTH, 2020, 23 : S45 - S45
  • [50] New insights into second-line (2L) choices after CDK4/6 inhibitors (CDK4/6i) in hormone receptor-positive (HR plus )/human epidermal growth factor 2-negative (HER2-) metastatic breast cancer (MBC) patients (pts): Preliminary results of the HERMIONE-13 study
    Cogliati, V.
    Rossi, E.
    Turla, A.
    Ambroggi, M.
    Berardi, R.
    Borella, F.
    Coltelli, L.
    De Giorgi, U. F. F.
    Ferro, A.
    Garrone, O.
    Giordano, M.
    Landucci, E.
    Mazzotta, M.
    Moretti, G.
    Palumbo, R.
    Vici, P.
    Zustovich, F.
    Riva, F.
    Capici, S.
    Cazzaniga, M. E.
    ANNALS OF ONCOLOGY, 2023, 34 : S358 - S358
12345